Ankylosingselected
selected 时间:2021-05-21 阅读:()
Item4.
InformationontheCompany1SelecteddevelopmentprojectsYearprojectenteredFormulation/currentPlannedfilingProject/CommonMechanismBusinessrouteofdevelopmentdates/currentproductnameofactionPotentialindicationfranchiseadministrationphasephaseABL001asciminibBCRABLinhibitorChronicmyeloidleukemia,3rdlineOncologyOral20162021/IIIACZ885canakinumabAntiinterleukin1beta2ndlinenonsmallcelllungcancerOncologySubcutaneousinjection20172021/IIImonoclonalantibody1stlinenonsmallcelllungcancerOncologySubcutaneousinjection20172021/IIIAdjuvantnonsmallcelllungcancerOncologySubcutaneousinjection20172022/IIIAVXS1011onasemno-SurvivalmotorneuronSpinalmuscularatrophyNeuroscienceIntravenousinfusion2018USapprovedgeneabepar-(SMN)gene(IVformulation)EUregistrationvovecreplacementtherapySpinalmuscularatrophyNeuroscienceIntrathecalinjection20182020/I(ITformulation)2AVXS201TBDMethylCpGbindingRettsyndromeNeuroscienceIntrathecalinjection20182023/Iprotein2(MECP2)genereplacementtherapyBYL7193alpelisibPI3KalphainhibitorPIK3CAmutanthormonereceptorpositiveOncologyOral2018USapproved(HR+)/humanepidermalgrowthfactorEUregistrationreceptor2negative(HER2)postmenopausaladvancedbreastcancer,2ndline(+fulvestrant)PIK3CA-relatedovergrowthspectrumOncologyOral20192020/IIITriplenegativebreastcancerOncologyOral20192023/IIIHormonereceptor-negative(HR-)/humanOncologyOral20192023/IIIepidermalgrowthfactorreceptor2-positive(HER2+)advancedbreastcancerOvariancancerOncologyOral20192023/IIIHeadandnecksquamouscellcarcinomaOncologyOral2019≥2024/IIICEE321TBDPan-JAKinhibitorAtopicdermatitisImmunology,Topical2019≥2024/IIHepatologyandDermatologyCFZ533iscalimabBlocking,nondepleting,SolidorgantransplantationImmunology,Intravenousinfusion20172023/IIantiCD40monoclonalHepatologyandantibodyDermatologySjgren'ssyndromeImmunology,Intravenousinfusion2018≥2024/IIHepatologyandDermatologyCosentyxsecukinumabAntiinterleukin17NonradiographicaxialspondyloarthritisImmunology,Subcutaneousinjection2015US/EUmonoclonalantibodyHepatologyandregistrationDermatologyPsoriaticarthritisheadtoheadstudyImmunology,Subcutaneousinjection20152020/IIIversusHumira(adalimumab)HepatologyandDermatologyAnkylosingspondylitisheadtoheadstudyImmunology,Subcutaneousinjection20152022/IIIversusSandozbiosimilarHyrimozHepatologyand(adalimumab)DermatologyHidradenitissuppurativaImmunology,Intravenousinfusion20172022/IIIHepatologyandDermatologyGiantcellarteritisImmunology,Intravenousinfusion2018≥2024/IIHepatologyandDermatologyLichenplanusImmunology,Intravenousinfusion2019≥2024/IIHepatologyandDermatologyCSJ117TBDAntithymicstromalSevereasthmaRespiratoryInhalation20182023/IIlymphopoietinmonoclonalantibodyfragmentECF843TBDBoundarylubricantDryeyeOphthalmologyEyedrops20172022/IIEntrestovalsartanandAngiotensinreceptor/ChronicheartfailurewithpreservedCardiovascular,Oral20122020/IIIsacubitrilneprilysininhibitorejectionfractionRenal(assodiumandMetabolismsaltcomplex)PostacutemyocardialinfarctionCardiovascular,Oral20152021/IIIRenalandMetabolism1ApprovedintheUSasZolgensmaforspinalmuscularatrophy(IVformulation)2TheFDAhasplacedapartialclinicalholdonAVXS-101intrathecaltrialsforspinalmuscularatrophypatientsbasedonfindingsinasmallpreclinicalanimalstudy.
3ApprovedintheUSasPiqrayforPIK3CAmutantHR+/HER2-postmenopausaladvancedbreastcancer,2ndline(+fulvestrant)Item4.
InformationontheCompany2YearprojectenteredFormulation/currentPlannedfilingProject/CommonMechanismBusinessrouteofdevelopmentdates/currentproductnameofactionPotentialindicationfranchiseadministrationphasephaseINC280capmatinibc-METinhibitorNonsmallcelllungcancerOncologyOral2014USregistrationSolidtumorsOncologyOral2019≥2024/IIJakaviruxolitinibJAK1/2inhibitorAcutegraftversushostdiseaseOncologyOral20162021/IIIChronicgraftversushostdiseaseOncologyOral20162021/IIIKAE609cipargaminPfATP4inhibitorMalariaEstablishedOral2012≥2024/IIMedicinesSeveremalariaEstablishedOral2019≥2024/IIMedicinesKAF156ganaplacideImidazolopiperazinesMalariaEstablishedOral2014≥2024/IIderivativeMedicinesKisqaliribociclibCDK4/6inhibitorHR+/HER2breastcancer(adjuvant)OncologyOral20182022/IIIKJX839inclisiranSmall-interferingRNAHyperlipidemiaCardiovascular,Subcutaneousinjection2019US/EU(PCSK9)RenalregistrationandMetabolismSecondarypreventionofcardiovascularCardiovascular,Subcutaneousinjection2019≥2024/IIIeventsinpatientswithelevatedlevelsRenalofLDL-CandMetabolismKymriahtisagen-CD19targetedchimericRelapsed/refractoryfollicularlymphomaOncologyIntravenousinfusion20172021/IIlecleucelantigenreceptorTcellimmunotherapyRelapsed/refractorydiffuselargeBcellOncologyIntravenousinfusion20182021/IIIlymphomain1strelapseRelapsed/refractorydiffuselargeBcellOncologyIntravenousinfusion2017≥2024/IIlymphoma(+pembrolizumab)LAM320clofazimineMycobacterialMultidrugresistanttuberculosisEstablishedOral20162021/IIIDNAbindingMedicinesLJC242tropifexor,FXRagonistandNonalcoholicsteatohepatitisImmunology,Oral2017≥2024/IIcenicrivirocCCR2/5inhibitorHepatologyand(infixed-doseDermatologycombination)LJN452tropifexorFXRagonistNonalcoholicsteatohepatitisImmunology,Oral2015≥2024/IIHepatologyandDermatologyLMI070branaplamSMN2RNAsplicingSpinalmuscularatrophyNeuroscienceOral2017≥2024/IImodulatorLNP023TBDFactorBinhibitorIgAnephropathyCardiovascular,Oral20182023/IIRenalandMetabolismC3glomerulopathyCardiovascular,Oral20182023/IIRenalandMetabolismParoxysmalnocturnalhemoglobinuriaCardiovascular,Oral20192023/IIRenalandMetabolismMembranousnephropathyCardiovascular,Oral2018≥2024/IIRenalandMetabolismLOU064TBDBTKinhibitorChronicspontaneousurticariaImmunology,Oral20172023/IIHepatologyandDermatology177Lu-TBDTargetedDNAMetastaticcastration-resistantOncologyIntravenousinfusion20182020/IIIPSMA-617destructionviaprostatecancerbeta-particleradiationLXE408TBDKinetoplastidVisceralleishmaniasisEstablishedOral2019≥2024/IIproteasomeinhibitorMedicinesMBG453TBDTIM-3antagonistMyelodysplasticsyndromeOncologyIntravenousinfusion20182021/IIAcutemyeloidleukemiaOncologyIntravenousinfusion2019≥2024/IIOMB157ofatumumabAntiCD20monoclonalRelapsingmultiplesclerosisNeuroscienceSubcutaneousinjection2015US/EUantibodyregistrationPDR001spartalizumabAntiPD1monoclonalMetastaticBRAFV600+OncologyIntravenousinfusion20172020/IIIantibodymelanoma(w/Tafinlar+Mekinist)Metastaticmelanoma(combo)OncologyIntravenousinfusion20172023/IIQBW251TBDCFTRpotentiatorChronicobstructivepulmonarydiseaseRespiratoryOral2017≥2024/IIQGE031ligelizumabHighaffinityantiIgEChronicspontaneousurticaria/Immunology,Subcutaneousinjection20172021/IIImonoclonalantibodychronicidiopathicurticariaHepatologyandDermatologyQMF149indacaterol,Longactingbeta2AsthmaRespiratoryInhalation2019EUregistrationmometasoneadrenergicagonistandfuroateinhaledcorticosteroid(infixeddosecombination)Item4.
InformationontheCompany3YearprojectenteredFormulation/currentPlannedfilingProject/CommonMechanismBusinessrouteofdevelopmentdates/currentproductnameofactionPotentialindicationfranchiseadministrationphasephaseQVM149indacaterol,Longactingbeta2AsthmaRespiratoryInhalation2019EUregistrationmometasoneadrenergicagonist,furoate,longactingmuscarinicglyco-antagonistandinhaledpyrroniumcorticosteroidbromide(infixeddosecombination)RTH2584brolucizumabAntiVEGFsinglechainNeovascular(wet)agerelatedmacularOphthalmologyIntravitrealinjection2019USapprovedantibodyfragmentdegenerationEUregistrationDiabeticmacularedemaOphthalmologyIntravitrealinjection20172021/IIIRetinalveinocclusionOphthalmologyIntravitrealinjection20182023/IIIProliferativediabeticretinopathyOphthalmologyIntravitrealinjection20192023/IIISAF312TBDTRPV1antagonistChronicocularsurfacepainOphthalmologyTopical2019≥2024/IISEG1015crizanlizumabPselectininhibitorSicklecelldiseaseOncologyIntravenousinfusion2019USapprovedEUregistrationTQJ230TBDAnti-apo(a)antisenseSecondarypreventionofcardiovascularCardiovascular,Subcutaneousinjection2018≥2024/IIIoligonucleotideeventsinpatientswithelevatedlevelsRenalandoflipoprotein(a)MetabolismUNR844TBDReductionofPresbyopiaCardiovascular,Eyedrops2017≥2024/IIdisulfidebondsRenalandMetabolismVAY736ianalumabAntiBAFF(BcellAutoimmunehepatitisImmunology,Subcutaneousinjection2016≥2024/IIactivatingfactor)HepatologyandmonoclonalantibodyDermatologyPrimarySjgren'ssyndromeImmunology,Subcutaneousinjection2015≥2024/IIHepatologyandDermatologyVPM087TBDInterleukin-1betaColorectalcancer,1stline;OncologyIntravenousinfusion2018≥2024/Ineutralizationrenalcellcarcinoma,1stlinemonoclonalantibodyXolairomalizumabAntiIgEmonoclonalNasalpolypsRespiratorySubcutaneousinjection2017US/EUantibodyregistrationFoodallergyRespiratorySubcutaneousinjection20192021/IIIZPL389adriforantHistamineH4receptorAtopicdermatitisImmunology,Oral2017≥2024/IIantagonistHepatologyandDermatology4ApprovedintheUSasBeovuforneovascular(wet)agerelatedmaculardegeneration5ApprovedintheUSasAdakveoforsicklecelldisease
InformationontheCompany1SelecteddevelopmentprojectsYearprojectenteredFormulation/currentPlannedfilingProject/CommonMechanismBusinessrouteofdevelopmentdates/currentproductnameofactionPotentialindicationfranchiseadministrationphasephaseABL001asciminibBCRABLinhibitorChronicmyeloidleukemia,3rdlineOncologyOral20162021/IIIACZ885canakinumabAntiinterleukin1beta2ndlinenonsmallcelllungcancerOncologySubcutaneousinjection20172021/IIImonoclonalantibody1stlinenonsmallcelllungcancerOncologySubcutaneousinjection20172021/IIIAdjuvantnonsmallcelllungcancerOncologySubcutaneousinjection20172022/IIIAVXS1011onasemno-SurvivalmotorneuronSpinalmuscularatrophyNeuroscienceIntravenousinfusion2018USapprovedgeneabepar-(SMN)gene(IVformulation)EUregistrationvovecreplacementtherapySpinalmuscularatrophyNeuroscienceIntrathecalinjection20182020/I(ITformulation)2AVXS201TBDMethylCpGbindingRettsyndromeNeuroscienceIntrathecalinjection20182023/Iprotein2(MECP2)genereplacementtherapyBYL7193alpelisibPI3KalphainhibitorPIK3CAmutanthormonereceptorpositiveOncologyOral2018USapproved(HR+)/humanepidermalgrowthfactorEUregistrationreceptor2negative(HER2)postmenopausaladvancedbreastcancer,2ndline(+fulvestrant)PIK3CA-relatedovergrowthspectrumOncologyOral20192020/IIITriplenegativebreastcancerOncologyOral20192023/IIIHormonereceptor-negative(HR-)/humanOncologyOral20192023/IIIepidermalgrowthfactorreceptor2-positive(HER2+)advancedbreastcancerOvariancancerOncologyOral20192023/IIIHeadandnecksquamouscellcarcinomaOncologyOral2019≥2024/IIICEE321TBDPan-JAKinhibitorAtopicdermatitisImmunology,Topical2019≥2024/IIHepatologyandDermatologyCFZ533iscalimabBlocking,nondepleting,SolidorgantransplantationImmunology,Intravenousinfusion20172023/IIantiCD40monoclonalHepatologyandantibodyDermatologySjgren'ssyndromeImmunology,Intravenousinfusion2018≥2024/IIHepatologyandDermatologyCosentyxsecukinumabAntiinterleukin17NonradiographicaxialspondyloarthritisImmunology,Subcutaneousinjection2015US/EUmonoclonalantibodyHepatologyandregistrationDermatologyPsoriaticarthritisheadtoheadstudyImmunology,Subcutaneousinjection20152020/IIIversusHumira(adalimumab)HepatologyandDermatologyAnkylosingspondylitisheadtoheadstudyImmunology,Subcutaneousinjection20152022/IIIversusSandozbiosimilarHyrimozHepatologyand(adalimumab)DermatologyHidradenitissuppurativaImmunology,Intravenousinfusion20172022/IIIHepatologyandDermatologyGiantcellarteritisImmunology,Intravenousinfusion2018≥2024/IIHepatologyandDermatologyLichenplanusImmunology,Intravenousinfusion2019≥2024/IIHepatologyandDermatologyCSJ117TBDAntithymicstromalSevereasthmaRespiratoryInhalation20182023/IIlymphopoietinmonoclonalantibodyfragmentECF843TBDBoundarylubricantDryeyeOphthalmologyEyedrops20172022/IIEntrestovalsartanandAngiotensinreceptor/ChronicheartfailurewithpreservedCardiovascular,Oral20122020/IIIsacubitrilneprilysininhibitorejectionfractionRenal(assodiumandMetabolismsaltcomplex)PostacutemyocardialinfarctionCardiovascular,Oral20152021/IIIRenalandMetabolism1ApprovedintheUSasZolgensmaforspinalmuscularatrophy(IVformulation)2TheFDAhasplacedapartialclinicalholdonAVXS-101intrathecaltrialsforspinalmuscularatrophypatientsbasedonfindingsinasmallpreclinicalanimalstudy.
3ApprovedintheUSasPiqrayforPIK3CAmutantHR+/HER2-postmenopausaladvancedbreastcancer,2ndline(+fulvestrant)Item4.
InformationontheCompany2YearprojectenteredFormulation/currentPlannedfilingProject/CommonMechanismBusinessrouteofdevelopmentdates/currentproductnameofactionPotentialindicationfranchiseadministrationphasephaseINC280capmatinibc-METinhibitorNonsmallcelllungcancerOncologyOral2014USregistrationSolidtumorsOncologyOral2019≥2024/IIJakaviruxolitinibJAK1/2inhibitorAcutegraftversushostdiseaseOncologyOral20162021/IIIChronicgraftversushostdiseaseOncologyOral20162021/IIIKAE609cipargaminPfATP4inhibitorMalariaEstablishedOral2012≥2024/IIMedicinesSeveremalariaEstablishedOral2019≥2024/IIMedicinesKAF156ganaplacideImidazolopiperazinesMalariaEstablishedOral2014≥2024/IIderivativeMedicinesKisqaliribociclibCDK4/6inhibitorHR+/HER2breastcancer(adjuvant)OncologyOral20182022/IIIKJX839inclisiranSmall-interferingRNAHyperlipidemiaCardiovascular,Subcutaneousinjection2019US/EU(PCSK9)RenalregistrationandMetabolismSecondarypreventionofcardiovascularCardiovascular,Subcutaneousinjection2019≥2024/IIIeventsinpatientswithelevatedlevelsRenalofLDL-CandMetabolismKymriahtisagen-CD19targetedchimericRelapsed/refractoryfollicularlymphomaOncologyIntravenousinfusion20172021/IIlecleucelantigenreceptorTcellimmunotherapyRelapsed/refractorydiffuselargeBcellOncologyIntravenousinfusion20182021/IIIlymphomain1strelapseRelapsed/refractorydiffuselargeBcellOncologyIntravenousinfusion2017≥2024/IIlymphoma(+pembrolizumab)LAM320clofazimineMycobacterialMultidrugresistanttuberculosisEstablishedOral20162021/IIIDNAbindingMedicinesLJC242tropifexor,FXRagonistandNonalcoholicsteatohepatitisImmunology,Oral2017≥2024/IIcenicrivirocCCR2/5inhibitorHepatologyand(infixed-doseDermatologycombination)LJN452tropifexorFXRagonistNonalcoholicsteatohepatitisImmunology,Oral2015≥2024/IIHepatologyandDermatologyLMI070branaplamSMN2RNAsplicingSpinalmuscularatrophyNeuroscienceOral2017≥2024/IImodulatorLNP023TBDFactorBinhibitorIgAnephropathyCardiovascular,Oral20182023/IIRenalandMetabolismC3glomerulopathyCardiovascular,Oral20182023/IIRenalandMetabolismParoxysmalnocturnalhemoglobinuriaCardiovascular,Oral20192023/IIRenalandMetabolismMembranousnephropathyCardiovascular,Oral2018≥2024/IIRenalandMetabolismLOU064TBDBTKinhibitorChronicspontaneousurticariaImmunology,Oral20172023/IIHepatologyandDermatology177Lu-TBDTargetedDNAMetastaticcastration-resistantOncologyIntravenousinfusion20182020/IIIPSMA-617destructionviaprostatecancerbeta-particleradiationLXE408TBDKinetoplastidVisceralleishmaniasisEstablishedOral2019≥2024/IIproteasomeinhibitorMedicinesMBG453TBDTIM-3antagonistMyelodysplasticsyndromeOncologyIntravenousinfusion20182021/IIAcutemyeloidleukemiaOncologyIntravenousinfusion2019≥2024/IIOMB157ofatumumabAntiCD20monoclonalRelapsingmultiplesclerosisNeuroscienceSubcutaneousinjection2015US/EUantibodyregistrationPDR001spartalizumabAntiPD1monoclonalMetastaticBRAFV600+OncologyIntravenousinfusion20172020/IIIantibodymelanoma(w/Tafinlar+Mekinist)Metastaticmelanoma(combo)OncologyIntravenousinfusion20172023/IIQBW251TBDCFTRpotentiatorChronicobstructivepulmonarydiseaseRespiratoryOral2017≥2024/IIQGE031ligelizumabHighaffinityantiIgEChronicspontaneousurticaria/Immunology,Subcutaneousinjection20172021/IIImonoclonalantibodychronicidiopathicurticariaHepatologyandDermatologyQMF149indacaterol,Longactingbeta2AsthmaRespiratoryInhalation2019EUregistrationmometasoneadrenergicagonistandfuroateinhaledcorticosteroid(infixeddosecombination)Item4.
InformationontheCompany3YearprojectenteredFormulation/currentPlannedfilingProject/CommonMechanismBusinessrouteofdevelopmentdates/currentproductnameofactionPotentialindicationfranchiseadministrationphasephaseQVM149indacaterol,Longactingbeta2AsthmaRespiratoryInhalation2019EUregistrationmometasoneadrenergicagonist,furoate,longactingmuscarinicglyco-antagonistandinhaledpyrroniumcorticosteroidbromide(infixeddosecombination)RTH2584brolucizumabAntiVEGFsinglechainNeovascular(wet)agerelatedmacularOphthalmologyIntravitrealinjection2019USapprovedantibodyfragmentdegenerationEUregistrationDiabeticmacularedemaOphthalmologyIntravitrealinjection20172021/IIIRetinalveinocclusionOphthalmologyIntravitrealinjection20182023/IIIProliferativediabeticretinopathyOphthalmologyIntravitrealinjection20192023/IIISAF312TBDTRPV1antagonistChronicocularsurfacepainOphthalmologyTopical2019≥2024/IISEG1015crizanlizumabPselectininhibitorSicklecelldiseaseOncologyIntravenousinfusion2019USapprovedEUregistrationTQJ230TBDAnti-apo(a)antisenseSecondarypreventionofcardiovascularCardiovascular,Subcutaneousinjection2018≥2024/IIIoligonucleotideeventsinpatientswithelevatedlevelsRenalandoflipoprotein(a)MetabolismUNR844TBDReductionofPresbyopiaCardiovascular,Eyedrops2017≥2024/IIdisulfidebondsRenalandMetabolismVAY736ianalumabAntiBAFF(BcellAutoimmunehepatitisImmunology,Subcutaneousinjection2016≥2024/IIactivatingfactor)HepatologyandmonoclonalantibodyDermatologyPrimarySjgren'ssyndromeImmunology,Subcutaneousinjection2015≥2024/IIHepatologyandDermatologyVPM087TBDInterleukin-1betaColorectalcancer,1stline;OncologyIntravenousinfusion2018≥2024/Ineutralizationrenalcellcarcinoma,1stlinemonoclonalantibodyXolairomalizumabAntiIgEmonoclonalNasalpolypsRespiratorySubcutaneousinjection2017US/EUantibodyregistrationFoodallergyRespiratorySubcutaneousinjection20192021/IIIZPL389adriforantHistamineH4receptorAtopicdermatitisImmunology,Oral2017≥2024/IIantagonistHepatologyandDermatology4ApprovedintheUSasBeovuforneovascular(wet)agerelatedmaculardegeneration5ApprovedintheUSasAdakveoforsicklecelldisease
- Ankylosingselected相关文档
- frequencyselected
- mesonselected
- lowestselected
- approachselected
- schemesselected
- detailedselected
DMIT：香港国际线路vps,1.5GB内存/20GB SSD空间/4TB流量/1Gbps/KVM,$9.81/月
DMIT怎么样？DMIT是一家美国主机商，主要提供KVM VPS、独立服务器等，主要提供香港CN2、洛杉矶CN2 GIA等KVM VPS，稳定性、网络都很不错。支持中文客服，可Paypal、支付宝付款。2020年推出的香港国际线路的KVM VPS，大带宽，适合中转落地使用。现在有永久9折优惠码：July-4-Lite-10OFF，季付及以上还有折扣，非 中国路由优化;AS4134，AS4837 均...
Webhosting24：$1.48/月起，日本东京NTT直连/AMD Ryzen 高性能VPS/美国洛杉矶5950X平台大流量VPS/1Gbps端口/
Webhosting24宣布自7月1日起开始对日本机房的VPS进行NVMe和流量大升级，几乎是翻倍了硬盘和流量，价格依旧不变。目前来看，日本VPS国内过去走的是NTT直连，服务器托管机房应该是CDN77*（也就是datapacket.com），加上高性能平台（AMD Ryzen 9 3900X+NVMe），还是有相当大的性价比的。此外在6月30日，又新增了洛杉矶机房，CPU为AMD Ryzen 9...
易探云服务器怎么过户/转让?云服务器PUSH实操步骤
易探云服务器怎么过户/转让?易探云支持云服务器PUSH功能，该功能可将云服务器过户给指定用户。可带价PUSH，收到PUSH请求的用户在接收云服务器的同时，系统会扣除接收方的款项，同时扣除相关手续费，然后将款项打到发送方的账户下。易探云“PUSH服务器”的这一功能，可以让用户将闲置云服务器转让给更多需要购买的用户！易探云服务器怎么过户/PUSH?1.PUSH双方必须为认证用户：2.买家未接收前，卖家...
selected为你推荐
-
内存nod32设置win7支持ipad阿片类药物:您需要知道什么供应商iphoneipadwifiipad wifi信号差怎么办win10445端口win7系统不能被telnet端口号，端口、服务什么全都开了css下拉菜单CSS如何把下拉菜单改为上拉菜单fusionchartsFusionCharts连接数据库你是怎么解决的，能告诉我吗？谢谢啦micromediawww.macromedia.com 是什么网站